RecruitingPhase 1NCT07437105
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
128 participants
Start Date
Feb 25, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria3
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (\>) 50 kg
- Male and Female participants of non-childbearing potential
Exclusion Criteria2
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVX-272
Suspension for Oral Administration.
DRUGPlacebo
Suspension for Oral Administration.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07437105
Related Trials
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Natural History of Bronchiectasis
NCT009435141 location
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT0542222238 locations
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT0615444711 locations
Natural History of Noncirrhotic Portal Hypertension
NCT024177401 location